Light Sciences Oncology Begins Clinical Trials Of Litx Therapy In Patients With Enlarged Prostate

Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. LSO plans to conduct a 12-patient, Phase I/I I dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter. "Treating patients with this serious quality-of-life problem is an important milestone for our Litx technology," said Llew Keltner, M.D., Ph.D., President and Chief Executive Officer of LSO. "We plan to continue to demonstrate the broader applicability of Litx beyond oncology." LSO currently is conducting Phase III clinical studies of Litx in patients with... [read full story]